[20]HuangSC, NgKF, LeeSE, et al.HER2 testing in paired biopsy and excision specimens of gastric cancer: the reliability of the scoring system and the clinicopathological factors relevant to discordance[J]. Gastric Cancer, 2016, 19(1):176–182. DOI: 10.1007/s10120-014-0453-0. [21]YoshidaH...
HER2 testing in paired biopsy and excision specimens of gastric cancer: the reliability of the scoring system and the clinicopathological factors relevant to discordance[J]. Gastric Cancer, 2016,19(1):176–182. DOI: 10.1007/s10120-014-0453-0 . 返回引文位置Google Scholar 百度学术 万方数据 [21...
Guidelines on pre-analytical techniques will help ensure optimal quality of testing Implementation of large QA / QC programmes will improve quality of testing (Full) Automation will help improve scoring quality New technologies promise more quantitative read-outs and assessment of dimerisation status ...
Reproducibility of Her2/neu scoring in gastric cancer and assessment of the 10%cut-off rule. Behrens HM,Warneke VS,B?ger C,Garbrecht N,Jüttner E,Klapper W,Mathiak M,Oschlies I,Rudolph U,Stuhlmann-Laeisz C,Trick D,R?cken C,Hufnagl P. Cancer Med . 2015...
HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol. 1992;10(4):599–605. Article CAS PubMed Google Scholar Schnitt SJ. Breast cancer in the 21st century: neu opportunities and neu challenges. Mod...
13.Park YS, Hwang HS, Park HJ, Ryu MH, Chang HM, Yook JH, Kim BS, Jang SJ, Kang YK. Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?Hum Pathol. 2012;43:413-422.[...
8, 12, 14, 19, 27, 28, 29, 30, 31, 32, 33, 34 This variability required to determine HER2 scoring guidelines, necessary for patients selection for targeted therapy,15, 23 similarly to what was done previously for breast cancer.35 The image analysis algorithm we set up to analyze ...
5). HER2+ was assigned according to international guidelines as IHC 2 + with amplification or IHC 3 +3. Figure 5 A schematic overview of HER2 scoring in breast cancer, as used in this study. Breast carcinomas are considered HER2- if the IHC score is 0. An IHC score 1 +...
Referring to the literature, HER2 immunoscoring differs not only between breast carcinoma and upper gastrointestinal adenocarcinoma, but there are different criteria for biopsies and surgical specimens of EAC/gastric adenocarcinoma (Table 2). Besides these conventional histopathological evaluation methods, the...
Immunohistochemical stainings were scored according to a 4-tiered scoring system recommended by the American Society of Clinical Oncology (ASCO)/College of American Pathologist (CAP) guidelines for gastric cancer resection specimens. The same scoring system is used in the ongoing DESTINY-PanTumor trial...